Imexpharm Corp
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and mine… Read more
Market Cap & Net Worth: Imexpharm Corp (IMP)
Imexpharm Corp (VN:IMP) has a market capitalization of $337.02 Million (₫8.56 Trillion) as of March 18, 2026. Listed on the VN stock exchange, this Vietnam-based company holds position #17509 globally and #101 in its home market, demonstrating a 3.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Imexpharm Corp's stock price ₫55600.00 by its total outstanding shares 154008962 (154.01 Million).
Imexpharm Corp Market Cap History: 2015 to 2026
Imexpharm Corp's market capitalization history from 2015 to 2026. Data shows growth from $45.20 Million to $337.02 Million (20.24% CAGR).
Imexpharm Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Imexpharm Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Imexpharm Corp's market cap is 0.00 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.00x
Imexpharm Corp's market cap is 0.00 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $85.45 Million | $1.40 Trillion | $162.39 Billion | 0.00x | 0.00x |
| 2020 | $133.22 Million | $1.37 Trillion | $209.70 Billion | 0.00x | 0.00x |
| 2021 | $187.61 Million | $1.27 Trillion | $189.09 Billion | 0.00x | 0.00x |
| 2022 | $148.48 Million | $1.64 Trillion | $223.54 Billion | 0.00x | 0.00x |
| 2023 | $153.84 Million | $1.99 Trillion | $299.56 Billion | 0.00x | 0.00x |
| 2024 | $284.89 Million | $2.21 Trillion | $320.86 Billion | 0.00x | 0.00x |
| 2025 | $318.23 Million | $2.44 Trillion | $349.14 Billion | 0.00x | 0.00x |
Competitor Companies of IMP by Market Capitalization
Companies near Imexpharm Corp in the global market cap rankings as of March 18, 2026.
Key companies related to Imexpharm Corp by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Imexpharm Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Imexpharm Corp's market cap moved from $45.20 Million to $ 337.02 Million, with a yearly change of 20.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₫337.02 Million | +5.90% |
| 2025 | ₫318.23 Million | +11.70% |
| 2024 | ₫284.89 Million | +85.18% |
| 2023 | ₫153.84 Million | +3.61% |
| 2022 | ₫148.48 Million | -20.86% |
| 2021 | ₫187.61 Million | +40.83% |
| 2020 | ₫133.22 Million | +55.90% |
| 2019 | ₫85.45 Million | -17.90% |
| 2018 | ₫104.08 Million | +6.11% |
| 2017 | ₫98.08 Million | +32.75% |
| 2016 | ₫73.89 Million | +63.45% |
| 2015 | ₫45.20 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Imexpharm Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $337.02 Million USD |
| MoneyControl | $337.02 Million USD |
| MarketWatch | $337.02 Million USD |
| marketcap.company | $337.02 Million USD |
| Reuters | $337.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.